FDA Grants Fast Track Designation to FG001 for High-Grade Glioma Surgery

The FDA has granted fast track designation to FG001, a fluorescent imaging agent targeting the urokinase-type plasminogen activator receptor (uPAR), for use as an intraoperative imaging agent guide during the surgical resection of high-grade glioma (HGG), according to a news release from the developer, FluoGuide.¹

The granting of fast track status follows the FDA’s clearance of an investigational new drug (IND) application in February 2026, which paved the way for the initiation of a US-based phase 2 registration trial.² The IND was initially submitted to the FDA in January 2026.³

Currently, the developer plans to initiate the planned US phase 2 trial, with the first patient expected to be enrolled in the second quarter of 2026. Investigators anticipate that 2 US trials will be required to support US regulatory approval of FG001 in patients with HGG.

“Fast track designation for FG001 is a meaningful recognition by FDA of the significant unmet need in [HGG] and the potential of our program to improve intraoperative tumor detection,” stated Donna Haire, chief operating officer of FluoGuide, in the press release.¹ “We greatly value the opportunity to work closely with the FDA and deeply appreciate their engagement as we continue to advance FG001 for patients facing this devastating cancer.”

Trial and Development Overview

According to the press release, FG001 is currently under clinical investigation for use in fluorescence-guided surgery in patients with HGG. Publicly available clinical trial registry data for FG001 remain limited, and no peer-reviewed efficacy or safety results have yet been published.

Fast track designation allows for more frequent interactions with the FDA, potential eligibility for accelerated approval and priority review, and rolling submission of a marketing application. These regulatory mechanisms are designed to streamline development timelines but do not imply clinical efficacy or approval.

FG001’s Background

FG001 is being developed as a targeted fluorescent imaging agent intended for intraoperative use. Such agents typically consist of a targeting moiety linked to a fluorophore, enabling real-time visualization of tumor tissue during surgery.

Fluorescence-guided surgery has emerged as a promising adjunct in neuro-oncology, with ongoing research focused on improving tumor specificity, depth of penetration, and signal-to-background ratio.⁴ Regulatory precedents, such as FDA approval of 5-aminolevulinic acid (5-ALA) for glioma surgery, provide a framework for the development of next-generation imaging agents.⁵

Clinical Context

Glioblastoma, the most aggressive form of high-grade glioma, has a median overall survival of approximately 14 months with current standard-of-care therapy, which includes maximal surgical resection followed by radiation and temozolomide chemotherapy.⁶ Despite advances in systemic therapy, outcomes remain poor, and recurrence is nearly universal.

Intraoperative visualization technologies have been developed to improve surgical precision. The most widely used agent, 5-ALA, is metabolized into a fluorescent compound that accumulates in tumor cells and has been shown to improve extent of resection and progression-free survival in randomized trials.⁵ However, limitations remain, including variability in fluorescence intensity and specificity, as well as logistical challenges related to administration and visualization.

Expert Framing and Future Directions

While the preliminary results are encouraging, independent investigators note that the definitive impact of FG001 on long-term survival remains to be proven in randomized, controlled registration trials. Beyond glioma, FG001 is also being investigated in head and neck cancer and lung cancer, reflecting the broad expression of uPAR across various solid malignancies.

“We are pleased achieving this important milestone in our endeavor to help patients with high-grade glioma,” concluded Morten Albrechtsen, chief executive officer of FluoGuide, in the release.¹

References

1. FluoGuide receives FDA fast track designation for FG001 in high-grade glioma. News release. FluoGuide. Published March 18, 2026. Accessed March 19, 2026. https://tinyurl.com/4yrcv5mt
2. FDA clears FluoGuide’s IND for FG001 in high-grade glioma, U.S. clinical trial remains on track. News release. FluoGuide. February 20, 2024. Accessed March 19, 2026. https://tinyurl.com/3nejb22x
3. FluoGuide submits an IND for FG001, to initiate first U.S. registration trial. News release. FluoGuide. January 21, 2026. Accessed March 19, 2026. https://tinyurl.com/mf2wjs2e
4. Hadjipanayis CG, Widhalm G, Stummer W. What is the surgical benefit of utilizing 5-ALA for fluorescence-guided surgery of malignant gliomas? Neurosurgery. 2015;77(5):663-673. https://doi.org/10.1227/NEU.0000000000000929
5. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised phase III trial. Lancet Oncol. 2006;7(5):392-401. doi:10.1016/S1470-2045(06)70665-9
6. Davis ME. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs. 2016;20(5):2-8. doi:10.1188/16.CJON.S1.2-8